Below are our currently enrolling studies for patients with different forms of lupus.
Sponsor: UCB Biopharma SRL
Protocol Number: SL0044
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
Detailed Information:
To learn more or see if you qualify: Click Here
Sponsor: AstraZeneca
Protocol Number: SUNFLOWER
The purpose of the SUNFLOWER study is to describe clinical outcomes, including DORIS remission, achieved following the initiation of anifrolumab 120 mg SC once weekly (QW) as add-on therapy to an anti-malarial, with or without GC; in patients not in LLDAS at enrolment.
Patients will be naïve to any prior conventional immunosuppressant including prior biologic therapy at enrolment. The study will also employ a tapering protocol for a systematic approach to GC tapering, seeking to understand better the proportion of patients in remission who can successfully withdraw chronic GC completely.
Detailed Information:
To learn more or see if you qualify: Click Here